Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19) (outSMART-LC) https://clinicaltrials.gov/ct2/show/NCT05877508 Summary: This company, Aerium Therapeutics, is trying antibody against the coronavirus in long Covid. It's double-blind with an expected enrollment of 30, with about 20 getting the medicine and 10 the placebo. They're giving the antibodies as a one-time dose, using the PROMIS questionnaire of general health as the primary outcome, and the COMPASS autonomic questionnaire and 6-minute walk test as secondary.
Aerium Therapeutics has only been in existence since 2022 - no track record, although the scientific pedigree seems sound: https://www.aeriumtx.com/ however it's not clear why the Monoclonal Antibodies route would be useful post COVID19 when it's not recommended as a preventative: Anti-SARS-CoV-2 Monoclonal Antibodies
The linked NIH page seems to say that monoclonal antibodies work on earlier strains, and they're not recommended because they're not as effective against later strains. Michael Peluso says as much in the NIH Research Roadmap webinar: "We're taking 30 people with long COVID attributed to a variant that the monoclonal would be thought to work against - so before September of [2022]."
